Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Michael D. Otremba, M.D.

Concepts (67)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Cranial Fossa, Anterior12013130.460 Why?
Prisons120151600.450 Why?
Hospital Charges120153580.450 Why?
Otitis12012200.430 Why?
Mastoiditis12012330.420 Why?
Agammaglobulinemia120121670.380 Why?
Maxilla120134640.370 Why?
Skull Base Neoplasms120132750.350 Why?
Antibodies, Monoclonal, Murine-Derived120126960.330 Why?
Immunoglobulins, Intravenous120126420.300 Why?
Poverty1201526210.230 Why?
Developing Countries1201527620.220 Why?
Neoplasms, Unknown Primary120181040.150 Why?
Neck Dissection120181950.140 Why?
Papillomavirus Infections2201815870.140 Why?
Radiotherapy, Adjuvant2201817640.140 Why?
Patient Credit and Collection12015160.130 Why?
Salivary Gland Neoplasms120182920.130 Why?
Head and Neck Neoplasms2201827000.120 Why?
Carcinoma, Squamous Cell2201840240.110 Why?
Oropharyngeal Neoplasms120174670.110 Why?
Human Rights120153060.110 Why?
Lymph Node Excision1201812430.100 Why?
Parotid Neoplasms120131510.100 Why?
Lymphatic Metastasis1201829080.090 Why?
Chemotherapy, Adjuvant1201834570.090 Why?
Neoplasm, Residual120139760.080 Why?
SEER Program1201315090.080 Why?
Lymphoma1201318750.060 Why?
Immunologic Factors1201215550.050 Why?
Antirheumatic Agents1201213210.050 Why?
Kaplan-Meier Estimate3201865350.050 Why?
Neoplasm Staging32018109680.040 Why?
Chronic Disease1201291100.040 Why?
Arthritis, Rheumatoid1201236580.040 Why?
Neoplasm Recurrence, Local1201391290.030 Why?
Drug Therapy120174980.030 Why?
Treatment Outcome32018625010.030 Why?
Prognosis32018289670.030 Why?
Propensity Score1201817530.030 Why?
Survival Rate22018127820.030 Why?
Papillomaviridae1201711180.030 Why?
Proportional Hazards Models22018123370.020 Why?
Female620183785100.020 Why?
Humans820187369400.020 Why?
Middle Aged520182131150.020 Why?
Follow-Up Studies12012389370.020 Why?
Tomography, X-Ray Computed12013200510.020 Why?
Young Adult22013562390.020 Why?
Retrospective Studies42018762000.020 Why?
Sex Distribution1201322950.020 Why?
Male520183490250.020 Why?
Age Distribution1201329040.020 Why?
Combined Modality Therapy1201886010.020 Why?
Magnetic Resonance Imaging12013352560.020 Why?
Survival Analysis12018102610.020 Why?
Aged420181626790.020 Why?
Disease-Free Survival1201368920.010 Why?
Incidence12013208830.010 Why?
Infant, Newborn12013254280.010 Why?
Infant12013348650.010 Why?
Child, Preschool12013407850.010 Why?
Aged, 80 and over12013577380.000 Why?
United States12013693620.000 Why?
Child12013767000.000 Why?
Adolescent12013852250.000 Why?
Adult120132132830.000 Why?
Otremba's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (67)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.